The Difference in the Effects on Microalbuminuria Depending on the Order of GLP-1RA and SGLT2i Therapy in Type 2 Diabetes

被引：0
|
作者：
Ohara, Masaya
Motoyama, Koka
Tamai, Anna
Sakura, Takeshi
Yakushiji, Yosuke
Hosoi, Masayuki
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-545-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
545-P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation
    Lopes, Antonio Cabral
    Lourenco, Olga
    Morgado, Manuel
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (11) : 1081 - 1088
  • [42] PROJECTING THE INCIDENCE AND COSTS OF MAJOR CARDIORENAL COMPLICATIONS OF TYPE 2 DIABETES WITH WIDESPREAD GLP-1 RA AND SGLT2I USE
    Morton, J.
    Marquina, C.
    Shaw, J. E.
    Liew, D.
    Ademi, Z.
    Magliano, D.
    VALUE IN HEALTH, 2022, 25 (07) : S404 - S404
  • [43] Predictors of Selection of a GLP1RA vs. SGLT2i in People with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
    Agarwal, Shubham
    Basit, Mujeeb A.
    Bowen, Michael E.
    Heitjan, Daniel
    Mai, Christine
    Marble, Kelsea
    Xiang, Zichang
    Lingvay, Ildiko
    DIABETES, 2024, 73
  • [44] MONITORING THE COMPARATIVE SAFETY OF SGLT2I VS GLP-1 RA IN OLDER ADULTS WITH TYPE 2 DIABETES BY FRAILTY STATUS
    Kutz, Alexander
    Patorno, Elisabetta
    Gopalakrishnan, Chandrasekar
    Kim, Dae
    INNOVATION IN AGING, 2021, 5 : 208 - 208
  • [45] Combined therapy with SGLT2i and GLP-1ra improves cardiovascular prognosis in a population with diabetes and overweigh or obesity. A real-world clinical practice study
    Garcia Vega, D.
    Cinza-Sanjurjo, S.
    Gonzalez-Juanatey, J. R.
    Eiras, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [46] Initiation of SGLT2i Versus GLP1-RA and the Risk of Chronic Kidney Disease in Persons with Type 2 Diabetes Mellitus
    Jensen, Simon K.
    Heide-Jorgensen, Uffe
    Andersen, Ina T.
    Thomsen, Reimar W. W.
    Christiansen, Christian Fynbo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 87 - 87
  • [47] Clinical, Demographic, Provider, and Formulary Characteristics Associated with Initiation of a SGLT2i or GLP-1RA among Medicare Beneficiaries with Type 2 Diabetes on Prior Oral Agents: A Cohort Study
    Luo, Jing
    Hernandez, Inmaculada
    Gabriel, Nico
    Gellad, Walid F.
    DIABETES, 2020, 69
  • [48] PROVIDER-REPORTED BARRIERS TO GUIDELINE-DIRECTED UTILIZATION OF SGLT2I/GLP-1RA AGENTS AMONG PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK FOR CARDIOVASCULAR DISEASE
    Qian, Frank
    Chaudhary, Richard
    Jonas, Zachary
    Ward, Charlotte
    Moran, Sara
    Quadir, Juweria
    Chen, Zsu-Zsu
    Benson, Mark D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1887 - 1887
  • [49] Effect of Combination SGLT2i and GLP-1RA Therapy on Glycemic Control, Body Weight, and Beta-Cell Function in Type 2 Diabetic (T2D) Subjects
    Martinez, Robert A.
    Al-Gburi, Karrar
    Al Jobori, Hussein
    Adams, John
    Abdul-Ghani, Muhammad
    Triplitt, Curtis
    Defronzo, Ralph A.
    Cersosimo, Eugenio
    DIABETES, 2017, 66 : LB44 - LB44
  • [50] The Risk of Major CV Events after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-toModerate CV Risk
    Patorno, Elisabetta
    Tesfaye, Helen
    Alix, Caroline
    Dicesare, Elyse C.
    Cromer, Sara Jane
    Everett, Brendan M.
    Glynn, Robert
    Wexler, Deborah J.
    Paik, Julie M.
    DIABETES, 2024, 73
12345